全文获取类型
收费全文 | 847136篇 |
免费 | 80905篇 |
国内免费 | 3618篇 |
专业分类
耳鼻咽喉 | 14132篇 |
儿科学 | 28478篇 |
妇产科学 | 19860篇 |
基础医学 | 113236篇 |
口腔科学 | 21376篇 |
临床医学 | 89358篇 |
内科学 | 179120篇 |
皮肤病学 | 23365篇 |
神经病学 | 63616篇 |
特种医学 | 31842篇 |
外国民族医学 | 76篇 |
外科学 | 143849篇 |
综合类 | 15040篇 |
现状与发展 | 74篇 |
一般理论 | 160篇 |
预防医学 | 57984篇 |
眼科学 | 19524篇 |
药学 | 54750篇 |
3篇 | |
中国医学 | 2360篇 |
肿瘤学 | 53456篇 |
出版年
2021年 | 8346篇 |
2020年 | 9112篇 |
2019年 | 7467篇 |
2018年 | 14877篇 |
2017年 | 13104篇 |
2016年 | 14807篇 |
2015年 | 15566篇 |
2014年 | 25147篇 |
2013年 | 30364篇 |
2012年 | 25655篇 |
2011年 | 26678篇 |
2010年 | 22672篇 |
2009年 | 25637篇 |
2008年 | 25484篇 |
2007年 | 25297篇 |
2006年 | 28089篇 |
2005年 | 23983篇 |
2004年 | 22816篇 |
2003年 | 20809篇 |
2002年 | 20424篇 |
2001年 | 39987篇 |
2000年 | 39831篇 |
1999年 | 33498篇 |
1998年 | 11377篇 |
1997年 | 9985篇 |
1996年 | 10197篇 |
1995年 | 9715篇 |
1994年 | 7953篇 |
1993年 | 7079篇 |
1992年 | 24285篇 |
1991年 | 24286篇 |
1990年 | 23327篇 |
1989年 | 23201篇 |
1988年 | 21018篇 |
1987年 | 20228篇 |
1986年 | 19318篇 |
1985年 | 17988篇 |
1984年 | 13224篇 |
1983年 | 11227篇 |
1982年 | 6404篇 |
1979年 | 11819篇 |
1978年 | 8444篇 |
1977年 | 7208篇 |
1976年 | 6811篇 |
1975年 | 7535篇 |
1974年 | 8712篇 |
1973年 | 8363篇 |
1972年 | 7953篇 |
1971年 | 7324篇 |
1970年 | 7114篇 |
排序方式: 共有10000条查询结果,搜索用时 546 毫秒
91.
92.
93.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
94.
95.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
96.
97.
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo oligometastases, and oligoprogressive disease likely have unique biologic underpinnings and natural histories. Evidence suggesting the existence of a subset of patients who harbor prostate cancer with limited metastatic potential currently includes disparate and overwhelmingly retrospective reports. Nevertheless, emerging prospective data have corroborated the “better-than-expected,” retrospectively observed outcomes, particularly in the setting of oligorecurrent prostate cancer. Improved functional imaging with prostate-specific membrane antigen-targeted strategies may enhance the identification of patients with oligometastatic prostate cancer in the short term. In the long term, refinement of the oligometastatic case definition likely will require biologic risk-stratification schemes. To determine optimal treatment strategies and identify patients most likely to benefit from metastasis-directed therapy, future efforts should focus on conducting high-quality, prospective trials with much-needed molecular correlative studies. 相似文献
98.
99.
100.
Angela J. Jacques-Tiura Deborah A. Ellis April Idalski Carcone Sylvie Naar Kathryn Brogan Hartlieb Elizabeth K. Towner Thomas N. Templin K.-L. Catherine Jen 《The Journal of adolescent health》2019,64(3):355-361